{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:05:25Z","timestamp":1790661925264,"version":"4.1.0"},"reference-count":4,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2026.1986405","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:41Z","timestamp":1790661041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary: Pembrolizumab-induced type-1 diabetes mellitus: clinical characteristics, therapeutic strategies, and prognosis from a retrospective analysis of 43 published cases"],"prefix":"10.3389","volume":"17","author":[{"given":"Shinichiro M.","family":"Koga","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Tokyo Metropolitan Center for Cancer and Infectious Diseases, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1947327","article-title":"Pembrolizumab-induced type-1 diabetes mellitus: clinical characteristics, therapeutic strategies, and prognosis from a retrospective analysis of 43 published cases","volume":"17","author":"Guo","year":"2026","journal-title":"Front Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.e23330","article-title":"Immune checkpoint inhibitor\u2013induced autoimmune type 1 diabetes: clinical characteristics and management outcomes from a multicenter retrospective study","volume":"44","author":"Banerji","year":"2026","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2185\/jrm.2024-030","article-title":"Early insulin averts hyperglycemic crisis in slow-onset durvalumab-induced checkpoint inhibitor-associated autoimmune diabetes mellitus","volume":"20","author":"Matsuda","year":"2025","journal-title":"J Rural Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1986405\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:42Z","timestamp":1790661042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1986405\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":4,"alternative-id":["10.3389\/fendo.2026.1986405"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1986405","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1986405"}}